GB2480159A - Compositions and methods for the treatment of altered a-synuclein function - Google Patents

Compositions and methods for the treatment of altered a-synuclein function Download PDF

Info

Publication number
GB2480159A
GB2480159A GB1108374A GB201108374A GB2480159A GB 2480159 A GB2480159 A GB 2480159A GB 1108374 A GB1108374 A GB 1108374A GB 201108374 A GB201108374 A GB 201108374A GB 2480159 A GB2480159 A GB 2480159A
Authority
GB
United Kingdom
Prior art keywords
alkyl
substituted
alkenyl
piperazino
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1108374A
Other languages
English (en)
Other versions
GB201108374D0 (en
Inventor
Amy B Manning-Bog
Birgitt Shule
J William Langston
Clifford A Lingwood
Michael S Mcgrath
Arasteh Ari Azhir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children
Parkinsons Institute
Neuraltus Pharmaceuticals Inc
Original Assignee
Hospital for Sick Children
Parkinsons Institute
Neuraltus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children, Parkinsons Institute, Neuraltus Pharmaceuticals Inc filed Critical Hospital for Sick Children
Publication of GB201108374D0 publication Critical patent/GB201108374D0/en
Publication of GB2480159A publication Critical patent/GB2480159A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1108374A 2008-11-14 2009-09-04 Compositions and methods for the treatment of altered a-synuclein function Withdrawn GB2480159A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19924308P 2008-11-14 2008-11-14
PCT/US2009/056116 WO2010056413A2 (en) 2008-11-14 2009-09-04 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION

Publications (2)

Publication Number Publication Date
GB201108374D0 GB201108374D0 (en) 2011-06-29
GB2480159A true GB2480159A (en) 2011-11-09

Family

ID=42170611

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1108374A Withdrawn GB2480159A (en) 2008-11-14 2009-09-04 Compositions and methods for the treatment of altered a-synuclein function

Country Status (9)

Country Link
US (2) US20120052053A1 (enExample)
EP (1) EP2361089A4 (enExample)
JP (2) JP2012508740A (enExample)
CN (1) CN102245180A (enExample)
AU (1) AU2009314447A1 (enExample)
BR (1) BRPI0920498A2 (enExample)
CA (1) CA2745451A1 (enExample)
GB (1) GB2480159A (enExample)
WO (1) WO2010056413A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2211856A4 (en) * 2007-11-29 2011-02-09 Hospital For Sick Children COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER
US9265735B2 (en) * 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
EP2533051A1 (en) * 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
US20140161896A1 (en) * 2011-08-04 2014-06-12 Ramot At Tel-Aviv University Ltd. Particles for the treatment of neurodegenerative diseases
CN103120697B (zh) * 2011-11-18 2015-10-07 复旦大学 鳞片酸在制备抗肿瘤药物中的应用
CN103120696A (zh) * 2011-11-18 2013-05-29 复旦大学 羊角衣酸在制备抗肿瘤药物中的应用
CN104069263A (zh) * 2013-03-27 2014-10-01 中国科学院上海药物研究所 一种用于治疗阿尔茨海默病的制剂及其制备方法
EP2962687B1 (en) 2013-04-02 2019-06-05 The Doshisha Tau aggregation inhibitor
CN105796579A (zh) * 2014-12-31 2016-07-27 中国科学院兰州化学物理研究所 抗老年性脑痴呆药物
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
AU2017238769A1 (en) * 2016-03-25 2018-11-15 Genzyme Corporation Biomarkers of proteopathies and uses thereof
CA3018893A1 (en) * 2016-03-28 2017-10-05 Syneurx International (Taiwan) Corp. Compositions containing tannic acids and uses thereof
CN105748460B (zh) * 2016-04-07 2018-11-02 大连医科大学附属第二医院 一种治疗老年痴呆的药物
ES2650175B1 (es) * 2016-04-15 2019-02-04 Servicio Andaluz De Salud Tratamiento de enfermedades neurodegenerativas
US10064833B2 (en) * 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
CN108143738A (zh) * 2016-12-02 2018-06-12 中国科学院大连化学物理研究所 一种治疗阿尔茨海默症的药物组合物及其制备和应用
CN107823198A (zh) * 2017-11-16 2018-03-23 黑龙江葆纳生物科技有限责任公司 北美圣草素在制备治疗阿尔茨海默病药物中的应用
US20210162316A1 (en) * 2017-12-07 2021-06-03 Syneurx International (Taiwan) Corp. Improved enrichment methods for preparing tannic acid compositions
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
WO2019169247A1 (en) * 2018-03-01 2019-09-06 The Johns Hopkins University DISCOVERY OF 2,6-DIMETHOXY-4-(5-PHENYL-4-THIOPHENE-2-YL-1H-IMIDAZOL-2-YL)-PHENOL (DPTIP) A SMALL MOLECULE INHIBITOR OF NEUTRAL SPHINGOMYELINASE 2 (nSMase-2) FOR THE TREATMENT OF NEURODEGENERATIVE AND ONCOLOGIC DISEASES
WO2020144753A1 (ja) * 2019-01-09 2020-07-16 公立大学法人大阪 神経変性疾患の予防又は治療薬
KR102102868B1 (ko) * 2019-05-14 2020-04-23 주식회사 노브메타헬스 고시페틴(Gossypetin)을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
US11154531B2 (en) 2020-02-08 2021-10-26 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
WO2021188575A1 (en) * 2020-03-16 2021-09-23 Coe William B Dietary supplement comprising aldehyde functional monoterpenoids
US10993958B1 (en) 2020-03-16 2021-05-04 William B. Coe Aldehyde functional monoterpenoids for the treatment of coronavirus infection
US12648926B2 (en) 2020-03-16 2026-06-09 William B. Coe Dietary supplement comprising aldehyde functional monoterpenoids
EP4139275A4 (en) 2020-04-23 2024-07-03 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
WO2022104011A1 (en) * 2020-11-12 2022-05-19 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CN112870250B (zh) * 2021-01-21 2022-08-12 广东盛普生命科技有限公司 防治器官纤维化的组合物及其应用与制剂
CN112704680B (zh) * 2021-01-21 2022-08-02 广东盛普生命科技有限公司 预防和/或治疗器官纤维化的组合物及其应用与制剂
WO2024026390A2 (en) * 2022-07-28 2024-02-01 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases
WO2024035236A1 (ko) * 2022-08-12 2024-02-15 포항공과대학교 산학협력단 고시페틴을 포함하는 지방간 개선용 조성물
CN115417789B (zh) * 2022-09-03 2023-08-04 郑州大学 一种治疗帕金森氏病的化合物、其制备方法以及复方药物组合物和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103959A2 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
WO2007003941A1 (en) * 2005-07-06 2007-01-11 Cambridge Enterprise Limited Modulation of autophagy by calpain inhibition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
ES2485369T3 (es) * 2005-06-08 2014-08-13 Amicus Therapeutics, Inc. Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas
WO2007140212A2 (en) * 2006-05-24 2007-12-06 Amicus Therapeutics, Inc. Tartrate salt of isofagomine and methods of use
DK2040548T3 (da) * 2006-06-23 2012-08-13 Amicus Therapeutics Inc Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
US20100041691A1 (en) * 2006-09-12 2010-02-18 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103959A2 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
WO2007003941A1 (en) * 2005-07-06 2007-01-11 Cambridge Enterprise Limited Modulation of autophagy by calpain inhibition

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BMC Medicine, Vol. 5(1), 2007, (Wolozin Benjamin; Wang Stanley W; Li Nien-Chen; Lee Austin; Lee Todd A; Kazis Lewis E), pages 1-11, ISSN 1741-7015 *
Brain Research, Vol. 1037(1-2), 2005, (Selley Michael L), pages 1-6, ISSN 0006-8993 *
Current Medicinal Chemistry, Vol. 14(1), 2007, (Rajanikant G K; Zemke D; Kassab M; Majid A), pages 103-112, ISSN 0929-8673 *
Current Pharmaceutical Design, Vol. 14(30), October 2008, (Ono Kenjiro; Hirohata Mie; Yamada Masahito), pages 3247-3266, ISSN 1381-6128 *
Journal of Neurochemistry, Vol. 105(5), June 2008 (published online 30 January 2008), (Pazit Bar-On, Leslie Crews, Andrew O. Koob, Hideya Mizuno, Anthony Adame, Brian Spencer, Eliezer Masliah), pages 1656-1667, ISSN 0022-3042 *

Also Published As

Publication number Publication date
CN102245180A (zh) 2011-11-16
BRPI0920498A2 (pt) 2019-09-24
JP2012508740A (ja) 2012-04-12
WO2010056413A2 (en) 2010-05-20
US20150044193A1 (en) 2015-02-12
GB201108374D0 (en) 2011-06-29
EP2361089A4 (en) 2012-08-22
US20120052053A1 (en) 2012-03-01
EP2361089A1 (en) 2011-08-31
AU2009314447A1 (en) 2010-05-20
JP2015127343A (ja) 2015-07-09
CA2745451A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
US20150044193A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION
Lin et al. N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease
AU2017279780B2 (en) Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
US8252789B2 (en) Compositions and methods for treating lysosomal disorders
US9393221B2 (en) Methods and compounds for reducing intracellular lipid storage
US20140235649A1 (en) Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
US5972928A (en) Methods for treatment of conditions associated with lactosylceramide
EP3989962B1 (en) Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease
US7662838B2 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
US20160075651A1 (en) Glycolipid inhibition using iminosugars
KR20130113430A (ko) 신경 연결의 발달 장애에 대한 ｅｒｋ 억제제
US20240374534A1 (en) Methods for treating mucopolysaccharidosis
Jakobkiewicz-Banecka et al. Combined therapies for lysosomal storage diseases
LeVine et al. Substrate reduction therapy for krabbe disease: exploring the repurposing of the antibiotic D-Cycloserine
AU2014265137A1 (en) Compositions and methods for the treatment of altered alpha-synuclein function
US20130072509A1 (en) Pterostilbene and statin combination for treatment of metabolic disease, cardiovascular disease, and inflammation
HK40127928A (en) Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease
ES2357742T3 (es) N-(5-adamantano-1-il-metoxi-pentil)desoxinojirimicina o una sal farmacéuticamente aceptable de la misma para el uso en el tratamiento de la resistencia a la insulina.
Fan et al. Pharmacological Chaperone Therapy for Fabry Disease
JP2020176063A (ja) ライソゾーム病の治療または予防のための医薬組成物
Spinedi Relevance of the Salvage Pathway to N-Hexanoylsphingosine Metabolic Downregulation in Human Neurotumor Cells: Implications for Apoptosis

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)